This report describes an analysis of infants born from October 2023-March 2024 that had respiratory syncytial virus (RSV) immunization coverage through nirsevimab monoclonal antibodies or maternal vaccination.
Categorised in: MMWR
This post was written by senioradmin
Comments are closed here.